Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial
Autore:
Sever, PS; Dahlof, B; Poulter, NR; Wedel, H; Beevers, G; Caulfield, M; Collins, R; Kjeldsen, SE; McInnes, GT; Mehlsen, J; Nieminen, M; OBrien, E; Ostergren, J;
Indirizzi:
Imperial Coll, Sch Med, London, England Imperial Coll London EnglandImperial Coll, Sch Med, London, England Sahlgrens Univ Hosp, Clin Trial Unit, Dept Med, Ostrava, Czech Republic Sahlgrens Univ Hosp Ostrava Czech Republic Med, Ostrava, Czech Republic Nordiska Halsovardshagskolan, Gothenburg, Sweden Nordiska Halsovardshagskolan Gothenburg Sweden olan, Gothenburg, Sweden City Hosp, Birmingham, W Midlands, England City Hosp Birmingham W Midlands England Birmingham, W Midlands, England St Bartholomews Hosp, London, England St Bartholomews Hosp London England Bartholomews Hosp, London, England Radcliffe Infirm, Oxford OX2 6HE, England Radcliffe Infirm Oxford England OX2 6HE Infirm, Oxford OX2 6HE, England Ulleval Sykehus, Oslo, Norway Ulleval Sykehus Oslo NorwayUlleval Sykehus, Oslo, Norway Western Infirm, Glasgow, Lanark, Scotland Western Infirm Glasgow Lanark Scotland Infirm, Glasgow, Lanark, Scotland HS Frederiksberg Hosp, Frederiksberg, Denmark HS Frederiksberg Hosp Frederiksberg Denmark osp, Frederiksberg, Denmark Univ Cent Hosp, Helsinki, Finland Univ Cent Hosp Helsinki FinlandUniv Cent Hosp, Helsinki, Finland Beaumont Hosp, Dublin 9, Ireland Beaumont Hosp Dublin Ireland 9Beaumont Hosp, Dublin 9, Ireland Karolinska Hosp, S-10401 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-10401 Hosp, S-10401 Stockholm, Sweden
Titolo Testata:
JOURNAL OF HYPERTENSION
fascicolo: 6, volume: 19, anno: 2001,
pagine: 1139 - 1147
SICI:
0263-6352(200106)19:6<1139:RDMABD>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; MYOCARDIAL-INFARCTION; SYSTOLIC HYPERTENSION; RANDOMIZED TRIAL; BLOOD-PRESSURE; OLDER PATIENTS; EVENTS; PRAVASTATIN; PREVENTION;
Keywords:
randomized trial; blood pressure; hypertension; coronary heart disease; cardiovascular events; calcium channel blocker; converting enzyme inhibitor; beta-blocker; thiazide; statin; placebo;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Sever, PS St Marys Hosp, Imperial Coll, Sch Med, NHLI Div, London W2 1NY, England St Marys Hosp London England W2 1NY iv, London W2 1NY, England
Citazione:
P.S. Sever et al., "Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial", J HYPERTENS, 19(6), 2001, pp. 1139-1147

Abstract

Objective To test the primary hypothesis that a newer antihypertensive treatment regimen (calcium channel blocker +/- an angiotensin converting enzyme inhibitor) is more effective than an older regimen (Beta-blocker a a diuretic) in the primary prevention of coronary heart disease (CHD). To test a second primary hypothesis that a statin compared with placebo will further protect against CHD endpoints in hypertensive subjects with a total cholesterol less than or equal to 6.5 mmol/l. Design Prospective, randomized, open, blinded endpoint trial with a double-blinded 2 x 2 factorial component. Setting Patients were recruited mainly from general practices. Patients Men and women aged 40-79 were eligible if their blood pressure was greater than or equal to 160 mmHg systolic or greater than or equal to 100 mmHg diastolic (untreated) or greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic (treated) at randomization. Interventions Patients received either amlodipine (5/10 mg) +/- perindopril (4/8 mg) or atenolol (50/100 mg) +/- bendroflumethiazide (1.25/2.5 mg) +K with further therapy as required to reach a blood pressure of less than or equal to 140 mmHg systolic and 90 mmHg diastolic. Patients with a total cholesterol of less than or equal to 6.5 mmol/l were further randomized to receive either atorvastatin 10 mg or placebo daily. Main outcome measure Non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD). Results 19 342 men and women were initially randomized, of these 10 297 were also randomized into the lipid-lowering limb. Allpatients had three or more additional cardiovascular risk factors. Conclusions The study has 80% power (at the 5% level) to detect a relativedifference of 20% in CHD endpoints between the calcium channel blocker-based regimen and the Beta-blocker-based regimen. The lipid-lowering limb of the study has 90% power at the 1% level to detect a relative difference of 30% in CHD endpoints between groups. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 13:15:08